Investors in the pharma/biotech sector eagerly wait for pipeline
updates as they play an important role in deciding whether or not
to invest in a particular company. Pipelines are of prime
importance as far as pharma/biotech companies which spend
significant funds and time in advancing their pipelines.
) provided an update on its pipeline. The company has initiated a
phase III program for its asthma candidate, tralokinumab. The phase
III program will assess the safety and efficacy of tralokinumab in
reducing the rate of asthma exacerbations in adults and adolescents
suffering from severe, inadequately controlled asthma despite
receiving inhaled corticosteroids plus long-acting β2-agonist.
The company initiated the phase III program on tralokinumab based
on results from a phase IIb study, which were presented at the 2014
American Thoracic Society International Conference in May.
AstraZeneca is also evaluating the candidate for the treatment of
mild-to-moderate idiopathic pulmonary fibrosis. A 72-week phase II
study evaluating the efficacy and safety of tralokinumab is
We are pleased with the pipeline progress at AstraZeneca. If
successfully developed and subsequently approved, tralokinumab will
boost the company's respiratory portfolio. AstraZeneca already has
experience in marketing several products like Symbicort and
Pulmicort in this area, which should prove beneficial if and when
tralokinumab receives approval.
Currently approved asthma products include Merck & Co. Inc.'s (
AstraZeneca presently carries a Zacks Rank #2 (Buy). Some
better-ranked stocks in the health care sector include Endo
) and Allergan (
). Both Allergan and Endo are Zacks Rank #1 (Strong Buy)
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
ENDO INTL PLC (ENDP): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis
To read this article on Zacks.com click here.